Table 3 Cox regression table to predict overall survival (OS) and progression-free survival (PFS) from those enroled in MRC myeloma trials from 1980 to 1997 (old trials) compared to the MRC Myeloma IX trial (2003–2008) and the ongoing NCRI Myeloma XI trial (2010–2016)

  SB2M group

≤4, 4–8, >8

1926

1.32 (1.19–1.46)

<.0001

SB2M group

≤4, 4–8, >8

145

1.04 (1.02, 1.06)

.0002

  Age group

<65 yrs, ≥65 yrs

1.25 (1.14–1.38)

<.0001

Age group

<65 yrs, ≥65 yrs

1.83 (1.55, 2.17)

<.0001

  % BMPCs

<20, 20–50, >50

1.17 (1.09–1.25)

<.0001

% BMPCs

<20, 20–50, >50

1.10 (0.98, 1.23)

.11

  ISS

I, II, III

1.18 (1.05–1.32)

.005

ISS

I, II, III

1.32 (1.15, 1.52)

<.0001

  Polyclonal IgM

Continuous

0.89 (0.77–1.03)

.12

Polyclonal IgM

Continuous

0.64 (0.42, 0.97)

.04

  Sex

Male, female

0.91 (0.83–1.00)

.06

Sex

Male, female

1.04 (0.88, 1.22)

.68

Genetic risk

SR, HR

1.65 (1.40, 1.95)

<.0001

  SB2M group

≤4, 4–8, >8

1921

1.21 (1.09–1.33)

.0002

SB2M group

≤4, 4–8, >8

1415

1.03 (1.01, 1.05)

.0002

  Age group

<65 yrs, ≥65 yrs

1.13 (1.03–1.24)

.01

Age group

<65 yrs, ≥65 yrs

1.75 (1.54, 1.99)

 < .0001

  % BMPCs

<20, 20–50, >50

1.23 (1.15–1.31)

<.0001

% BMPCs

<20, 20–50, >50

1.05 (0.96, 1.28)

.33

  ISS

I, II, III

1.19 (1.06–1.32)

.003

ISS

I, II, III

1.16 (1.15, 1.51)

.005

  Polyclonal IgM

Continuous

0.84 (0.73–0.98)

.02

Polyclonal IgM

Continuous

0.62 (0.46, 0.83)

.002

  Sex

Male, female

0.91 (0.83–0.99)

.04

Sex

Male, female

1.13 (0.99, 1.28)

.07

Genetic risk

SR, HR

1.39 (1.22, 1.58)

<.0001